These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27240457)

  • 1. Biological Response Modifier in Cancer Immunotherapy.
    Liu R; Luo F; Liu X; Wang L; Yang J; Deng Y; Huang E; Qian J; Lu Z; Jiang X; Zhang D; Chu Y
    Adv Exp Med Biol; 2016; 909():69-138. PubMed ID: 27240457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
    Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
    Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Cancer Vaccines.
    Ye Z; Li Z; Jin H; Qian Q
    Adv Exp Med Biol; 2016; 909():139-67. PubMed ID: 27240458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.
    Wittig B; Schmidt M; Scheithauer W; Schmoll HJ
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):31-44. PubMed ID: 25577571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the Microbiome to Enhance Cancer Immunotherapy.
    Nelson MH; Diven MA; Huff LW; Paulos CM
    J Immunol Res; 2015; 2015():368736. PubMed ID: 26101781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of cancer: biological response modifiers and cytotoxic cell therapy.
    Hillman GG; Haas GP; Wahl WH; Callewaert DM
    Biotherapy; 1992; 5(2):119-29. PubMed ID: 1524952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cells and toll-like receptors in cancer therapy.
    Wang RF
    Cancer Res; 2006 May; 66(10):4987-90. PubMed ID: 16707417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod.
    Spaner DE; Miller RL; Mena J; Grossman L; Sorrenti V; Shi Y
    Leuk Lymphoma; 2005 Jun; 46(6):935-9. PubMed ID: 16019542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
    Lombardi VC; Khaiboullina SF; Rizvanov AA
    Eur J Clin Invest; 2015 Jan; 45 Suppl 1():1-8. PubMed ID: 25524580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
    Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
    J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.
    Huen AO; Rook AH
    Curr Opin Oncol; 2014 Mar; 26(2):237-44. PubMed ID: 24441505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor agonists in cancer therapy.
    Adams S
    Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
    Lee SN; Jin SM; Shin HS; Lim YT
    Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.
    Xun Y; Yang H; Kaminska B; You H
    J Hematol Oncol; 2021 Oct; 14(1):176. PubMed ID: 34715891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
    Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
    IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
    Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
    Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression in actinic keratoses: pharmacological modulation by imiquimod.
    Lysa B; Tartler U; Wolf R; Arenberger P; Benninghoff B; Ruzicka T; Hengge UR; Walz M
    Br J Dermatol; 2004 Dec; 151(6):1150-9. PubMed ID: 15606509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-inducing program of human dendritic cells in response to BCG cell-wall skeleton (CWS), which reflects adjuvancy required for tumor immunotherapy.
    Ishii K; Kurita-Taniguchi M; Aoki M; Kimura T; Kashiwazaki Y; Matsumoto M; Seya T
    Immunol Lett; 2005 May; 98(2):280-90. PubMed ID: 15860229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.